ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in two upcoming investor conferences in November 2024. The company will be featured in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference on November 11 at 10:30 a.m. ET and the Jefferies London Healthcare Conference on November 21 at 12:00 p.m. GMT. Live webcasts of both discussions will be accessible through ORIC's investor website section, with replays available for 90 days after the events.
ORIC Pharmaceuticals (Nasdaq: ORIC), un'azienda oncologica in fase clinica, ha annunciato la sua partecipazione a due conferenze per investitori previste per novembre 2024. L'azienda sarà presente in discussioni informali alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim l'11 novembre alle 10:30 ET e alla Conferenza Sanitaria di Jefferies a Londra il 21 novembre alle 12:00 GMT. Le dirette web delle due discussioni saranno disponibili nella sezione degli investitori del sito web di ORIC, con repliche accessibili per 90 giorni dopo gli eventi.
ORIC Pharmaceuticals (Nasdaq: ORIC), una empresa de oncología en etapa clínica, ha anunciado su participación en dos conferencias de inversores programadas para noviembre de 2024. La compañía aparecerá en charlas informales en la Conferencia Inaugural de Innovación en Salud de Guggenheim el 11 de noviembre a las 10:30 a.m. ET y en la Conferencia de Salud de Jefferies en Londres el 21 de noviembre a las 12:00 p.m. GMT. Las transmisiones en vivo de ambas discusiones estarán disponibles a través de la sección de inversores del sitio web de ORIC, con repeticiones accesibles durante 90 días después de los eventos.
ORIC Pharmaceuticals (Nasdaq: ORIC), 임상 단계의 종양학 회사,가 2024년 11월에 예정된 두 가지 투자자 회의에 참여한다고 발표했습니다. 이 회사는 11월 11일 오전 10시 30분 ET에 있는 구겐하임의 첫 번째 의료 혁신 회의와 11월 21일 오후 12시에 열리는 제퍼리의 런던 의료 회의에서 화로 대담에 참여합니다. 두 토론의 라이브 웹캐스트는 ORIC의 투자자 웹사이트 섹션을 통해 접근할 수 있으며, 이벤트 종료 후 90일 동안 다시 시청할 수 있습니다.
ORIC Pharmaceuticals (Nasdaq: ORIC), une entreprise d'oncologie en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs en novembre 2024. L'entreprise sera présente lors de discussions informelles à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim le 11 novembre à 10h30 ET et à la Conférence de Santé de Jefferies à Londres le 21 novembre à 12h00 GMT. Les diffusions en direct des deux discussions seront accessibles via la section investisseurs du site web d'ORIC, avec des rediffusions disponibles pendant 90 jours après les événements.
ORIC Pharmaceuticals (Nasdaq: ORIC), ein Unternehmen in der klinischen Onkologie, hat seine Teilnahme an zwei kommenden Investorenkonferenzen im November 2024 bekannt gegeben. Das Unternehmen wird in Kamin-Diskussionen auf der Inaugural Healthcare Innovation Conference von Guggenheim am 11. November um 10:30 Uhr ET und der Jefferies London Healthcare Conference am 21. November um 12:00 Uhr GMT vertreten sein. Live-Webcasts beider Diskussionen werden über den Investorenteil von ORICs Website zugänglich sein, mit Wiederholungen, die 90 Tage nach den Veranstaltungen verfügbar sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November:
- Guggenheim’s Inaugural Healthcare Innovation Conference – Participating in a fireside chat on Monday, November 11, 2024, at 10:30 a.m. ET
- Jefferies London Healthcare Conference – Participating in a fireside chat on Thursday, November 21, 2024, at 12:00 p.m. GMT
Live webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What investor conferences is ORIC Pharmaceuticals attending in November 2024?
When is ORIC's fireside chat at the Guggenheim Healthcare Conference?
How long will ORIC's conference webcasts be available for viewing?
Where can investors watch ORIC's conference presentations?
